INFORMATION OF THE SECOND STATE OF THE SECOND SECON

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

1

OF

2

Docket Number 47508-518 HYZ-030CPCN3 Application Number 09/777,526

Applicant Agrawal, et al.

Filing Date 2/6/2001 Group Art Unit 1635

· · · · · · · · · · · · · · · · · · ·		U.	S. Patent Documer	nts		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,510,239	4/23/96	Baracchini, et al.			
					 	

EXAMINER	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INIT	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
1	WO94/23028	10/13/1994	WO				
	WO96/12497	5/2/1996	WO				
	WO97/11171	3/27/1997	WO				
	ļ				-	, _	
					<u></u>		

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
- 1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in Applied Antisense Oligonucleotide Technology (Stein and Krieg, Eds.), pp. 365-385 (1998)
, ,	Agrawal, "Preface", in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. v-vii (1996)
	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. 247-270 (1996)
, ,	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
•	Crooke; "Basic Principles of Antisense Therapeutics"; in Antisense Research and Application (Crooke, Ed.); pp. 1-50 (1998)
1	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
• 1	Friedmann: "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation if not conformation and not considered. Include come with next come	on is in conformance with MPEP § 609: Draw ne thirduga vitation
max txen ditw yaar abulaal barahaan aan aan aan aan aan ii	munication to applicant.

BOSTON 1514336v1

OCT 1 0 2002

TECH CENTER 1600/2900


Subt. For, PT	ORMATION I	DISCLO	DSUPPE I P	Docket Num HYZ-030CF	Application Number 09/777,526
	IN AN APPL	ICATIO	DNY T	Appli Agrawa	
Sheet	1	OF	To English	Filing Date February 6, 2001	Group Art Unit 1635

U.S. Patent Documents							
EXAMINER JUITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
33	4,309,404	1/5/1982	DeNeale et al.				
	4,309,406	1/5/1982	Guley et al.				
	4,556,552	12/3/1985	Porter et al.				
	4,704,295	11/3/1987	Porter et al.				
	5,149,797	9/22/1992	Pederson et al.				
	5,220,007	6/15/1993	Pederson et al.				
	5,248,670	9/28/1993	Draper et al.				
	5,271,941	12/21/1993	Cho-Chung				
	5,403,709	4/4/1995	Agrawal et al.				
	5,442,049	8/15/1995	Anderson et al.			•	
	5,470,967	11/28/1995	Huie et al.				
	5,514,577	5/7/1996	Draper, et al.				
	5,578,716	11/26/1996	Szyf,. et al.				
	5,612,212	3/18/1997	Gewirtz		•		
	5,652,355	7/29/1997	Metelev, et al.				
	5,969,117	10/19/1999	Agrawal				
4.4	6,143,881	11/7/2000	Metelev, et al.				

		Foreig	n Patent Docur	nents			
EXAMINER	DOCUMENT		00111T0V	CLACC	SUBCLASS	TRANSI	ATION
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
Py .	92/03568	3/5/1992	WO				
4	93/08296	4/29/1993	WO				
	93/13114	7/8/1993	WO				
-	93/13740	7/22/1993	WO	·			
-	93/19203	9/30/1993	WO				
1 .	94/02498	2/3/1994	WO				
-	94/15619	7/21/1994	WO		·		
42	94/19945	9/15/1994	WO				

EXAMINER DUL DO	DATE CONSIDERED 6/26/03					
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.						

BOSTON 1609152v1



Applicants Coon

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number HYZ-030CPCN3 47508-518

Application Number 09/777,526

Applicant **Agrawal**

Filing Date OF Sheet 1 1 2/6/2001

Group Art Unit 1635

	U.S	. Patent Docume	ents		
DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
5,587,361	12/24/1996	Cook, et al.			
				-	
				+	
			 	 	
	NUMBER	DOCUMENT DATE	DOCUMENT DATE NAME	DOCUMENT DATE NAME CLASS	NUMBER DATE NAME CLASS SUBCLASS

		Fore	eign Patent Docur	ments			
EXAMINER DOCUME	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL	NUMBER	DATE	COUNTRY			YES	NO
j							
		·					
<u> </u>							
i							

	Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
A1	
A2	
A3	
A4	
A5	
A6	
B1	
B2	
B3	
B4	
B5	
B6	
B7	
B8	

EXAMINER	AQC	<u>ا</u>
		-

DATE CONSIDERED \$100

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Azzglicants Cozan

W C P H AND D LLF

INFORMATION DISCLOSURE IN AN APPLICATION				Docket Number 47508-518 HYZ-030CPCN3 Applicant Agrawal, et al.			
Sheet	e several sh	OF OF	22	Filing Date 2/6/2001	Group Art Unit		

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
724	5,510,239	4/23/96	Baracchini, et al.			
					<u> </u>	
	<u>.</u>					
	· · ·				1	
					 	,.

EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						YES	NO
XX	WO94/23028	10/13/1994	WO				
120	WO96/12497	5/2/1996	WO				
1	WO97/11171	3/27/1997	WO				
					1		

	'	
		Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
Lest	A1	Agrawal; "In Vivo Pharmacokinetics of Oligonucleotides"; in Applied Antisense Oligonucleotide Technology (Stein and Krieg, Eds.), pp. 365-385 (1998)
	A2	Agrawal, "Preface", in <u>Methods in Molecular Medicine</u> : Antisense Therapeutics (Agrawal, Ed.); pp. v-vii (1996)
	A3	Agrawal, et al.; "Comparative Pharmacokinetics of Antisense Oligonucleotides"; in Methods in Molecular Medicine: Antisense Therapeutics (Agrawal, Ed.); pp. 247-270 (1996)
	A4	Branch; "A Good Antisense Molecule is Hard to Find"; TIBS 23; pp. 45-50, February 1998
	AS	Crooke; "Basic Principles of Antisense Therapeutics"; in Antisense Research and Application (Crooke, Ed.); pp. 1-50 (1998)
(Au)	A6	Crystal; "Transfer of Genes to Humans: Early Lessons and Obstacles to Success"; Science; vol. 270, pp. 404-410 (1995)
AN.	B1	Friedmann; "Overcoming the Obstacles"; Scientific American; pp. 96-101, June 1997

EXAMINER, (DATE CONSIDERED
	hel. 1.
- Valle FU	1 4/10/04
EYAMINED: Intital if allocation to accord and the transport	and distance in the second sec

EXAMINEH: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1514336v1

W C P H AND D LLP

Subt. For, PTO-1449 Docket Number **Application Number** 47508-518 09/777,526 INFORMATION DISCLOSURE HYZ-030CPCN3 IN AN APPLICATION Applicant Agrawal, et al. (Use several sheets if necessary) Filing Date Group Art Unit Sheet 2 OF 2 2/6/2001 1635

49	B2	Monia, et al.; "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase"; Nature Medicine; Vol. 2, No. 6, pp. 668-675, June 1996
	B3	Schofield et al.; "Non-viral Approaches to Gene Therapy"; British Medical Bulletin; Vol. 51, No. 1, pp. 56-71 (1995)
	B4	Verma, et al.; "Gene Therapy – Promises, Problems, and Prospects"; Nature; Vol. 389, pp. 239-242, September 1997
	B5	Vlassov, et al.; "In Vivo Pharmacokinetics of Oligonucleotides Following Administration by Different Routes"; in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> (Akhtar, Ed.); pp. 71-83 (1995).
494	B6	Vlassov, et al.; "Penetration of Oligonucleotides into Mouse Organism through Mucosa and Skin"; FEBS Letters; Vol. 327, No. 3, pp. 271-274; August 1993
	B7	
	B8	
	B9	
	B10	
	B11	
	B12	
	B13	
	B14	
	B15	
	C1	
	C2	
	Ca	
	C4	
	C5	
	6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	
	D1	
	D2	
	D3	
		

EXAMINER DATE CONSIDERED 6/10/0V

EXAMINER: initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

BOSTON 1514336v1